Drugs for Lipid Disorders Study Notes

Chapter 23: Drugs for Lipid Disorders

Drugs at a Glance

  • HMG-COA Reductase Inhibitors (Statins)

    • atorvastatin (Lipitor)

  • Bile Acid Sequestrants

    • cholestyramine (Questran)

    • niacin

  • Fibric Acid Drugs

    • gemfibrozil (Lopid)

  • Miscellaneous Drugs for Dyslipidemia

Learning Outcomes

After reading this chapter, the student should be able to:

  1. Summarize the link between high blood cholesterol, low density lipoprotein (LDL) levels, and cardiovascular disease.

  2. Compare and contrast the different types of lipids.

  3. Illustrate how lipids are transported through the blood.

  4. Compare and contrast the different types of lipoproteins.

  5. Give examples of how cholesterol and low-density lipoprotein levels can be controlled through nonpharmacologic means.

  6. For each of the drug classes listed in Drugs at a Glance, know representative drug examples, and explain their mechanisms of action, primary actions, and important adverse effects.

  7. Explain the nurse's role in the pharmacologic management of lipid disorders.

  8. Use the nursing process to care for patients receiving pharmacotherapy for lipid disorders.

Key Terms

  • apoprotein: A protein that binds lipids to form lipoproteins, involved in lipid transport in the bloodstream.

  • atherosclerosis: A condition characterized by the buildup of plaque in the arterial walls, leading to cardiovascular disease.

  • bile acid sequestrants: Drugs that bind bile acids in the intestine to lower cholesterol levels.

  • dyslipidemia: Abnormal levels of lipoproteins, either too high or too low.

  • high-density lipoprotein (HDL): Often referred to as "good cholesterol," it transports cholesterol from the tissues back to the liver for excretion.

  • HMG-CoA reductase: An enzyme critical for cholesterol synthesis; inhibited by statins.

  • hypercholesterolemia: Elevated levels of cholesterol in the blood, a risk factor for cardiovascular disease.

  • hyperlipidemia: High levels of lipids, including cholesterol and triglycerides, in the blood.

  • lecithins: Phospholipids found in biological membranes, previously thought to help lower cholesterol levels.

  • lipoproteins: Complexes of lipids and proteins that transport lipids in the blood.

  • low-density lipoprotein (LDL): Often referred to as "bad cholesterol," it transports cholesterol from the liver to the tissues, contributing to plaque buildup.

  • phospholipids: Lipids that form cellular membranes; crucial for lipid structure and function.

  • reverse cholesterol transport: The process by which HDL transports cholesterol from tissues back to the liver.

  • rhabdomyolysis: A serious adverse effect characterized by muscle breakdown, potentially leading to acute renal failure, associated with certain lipid-lowering drugs.

  • steroids: A class of lipids characterized by a four-ring structure; includes cholesterol, which is important in membrane structure and hormone synthesis.

  • sterol nucleus: The core structure of steroids, including cholesterol.

  • triglycerides: The main form of fat storage in the body, composed of glycerol and three fatty acids.

  • very low-density lipoprotein (VLDL): A type of lipoprotein primarily responsible for transporting triglycerides.

23.1 Types of Lipids

  • Triglycerides:

    • Description: Comprises 90% of total lipids in the body, made of glycerol and three fatty acids.

    • Fatty Acid Types: Saturated (single bonds, increased cardiovascular risk) and unsaturated (double bonds, beneficial). Omega-3 fatty acids (double bond at the third carbon) considered "good" fats.

    • Role: Major form of energy storage and source of fuel.

  • Phospholipids:

    • Description: Comprised of glycerol, two fatty acids, and a phosphate group.

    • Function: Essential for cellular membrane structure.

    • Best Known Type: Lecithins, prevalent in egg yolks and soybeans, previously thought to lower cholesterol but lack proven benefits.

  • Steroids:

    • Description: Share a common sterol nucleus structure. Cholesterol is a primary steroid associated with atherosclerosis.

    • Function: Vital to cell membrane integrity, serves as a precursor for hormones (vitamin D, bile acids, various steroids).

    • Sources: 75% of blood cholesterol synthesized by the liver; 25% derived from animal products.

    • Dietary Recommendations: Limit saturated fat intake to 5-6% of total calories (13g/day for a 2000 calorie diet).

23.2 Lipoproteins

  • Overview: Lipids' insolubility necessitates transport through blood as lipoproteins, which include cholesterol, triglycerides, phospholipids, and apoproteins.

  • Types of Lipoproteins:

    • High-Density Lipoprotein (HDL):

    • Composition: Highest apoprotein content (up to 50%).

    • Function: Transports cholesterol from tissues to the liver for excretion (reverse cholesterol transport).

    • Characterization: “Good” cholesterol, promotes cholesterol removal from body.

    • Low-Density Lipoprotein (LDL):

    • Function: Main cholesterol carrier from liver to tissues, integral for cell membrane and steroid synthesis.

    • Characterization: Associated with plaque buildup in arteries, termed “bad” cholesterol.

    • Very Low-Density Lipoprotein (VLDL):

    • Function: Carries triglycerides in the blood.

    • Role: Transition to LDL as triglycerides are depleted.

  • Terminology:

    • Hyperlipidemia: General term for elevated lipid levels.

    • Hypercholesterolemia: Specific type of hyperlipidemia characterized by high cholesterol levels.

    • Dyslipidemia: Abnormal lipoprotein levels, either decreased or increased.

23.3 LDL and Cardiovascular Disease

  • Relationship: High LDL levels correlate with increased risk of cardiovascular disease, including strokes and heart attacks.

  • Assessment: Evaluating LDL and HDL values provides a more accurate risk profile than total cholesterol levels.

  • LDL Classes: Recent research categorizes LDL into subclasses, such as lipoprotein (a), linked to heart disease and plaque formation.

  • Recent Guidelines: 2013 ACC/AHA revisions emphasize risk-factor assessment rather than strict target LDL levels for treatment decisions.

23.4 Controlling Lipid Levels Through Lifestyle Changes

  • Lifestyle Interventions: Essential in managing lipid levels, often more effective than pharmacology alone in early stages.

    • Key Modifications:

    • Regular blood lipid monitoring.

    • Optimal weight management.

    • Structured exercise routines.

    • Diet adjustments: reduce saturated/trans fats, increase soluble fiber.

    • Tobacco cessation.

  • Dietary Recommendations: Advise reducing cholesterol intake by less than 300 mg/day, although more recent studies suggest a low-cholesterol diet has minimal effects as the liver compensates by producing cholesterol.

23.5 Pharmacotherapy with Statins

  • Statins Overview: Block HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, decreasing LDL levels significantly.

  • Mechanism: Statins lead to increased LDL receptor production in the liver, enhancing LDL clearance from blood.

    • Outcome: Statins can reduce LDL by more than 50% and have been shown to prevent various cardiovascular events:

    • Example: 1 in 3 heart attacks/strokes preventable.

  • Administration: Orally given, might be more effective if taken in the evening for certain short half-life statins (Lovastatin/Simvastatin).

  • Adverse Effects: Minor effects include headache, fatigue, and GI discomfort, while severe consequences include myopathy and rhabdomyolysis (muscle breakdown leading to acute renal failure).

23.6 Bile Acid Sequestrants

  • Function: Bind bile acids in the intestine, promoting cholesterol elimination via feces. While classes such as cholestyramine were once first-line treatments, they are now used mainly in combination with statins or for specific population cases.

  • Adverse Effects: GI related, including constipation, bloating, and the potential for nutrient deficiencies due to malabsorption.

23.7 Pharmacotherapy with Niacin

  • Classification: A B-complex vitamin (B3), effective for lowering triglycerides and VLDL levels at doses much higher than dietary needs.

  • Mechanism: Reduces VLDL which in turn lowers LDL levels.

  • Adverse Effects: High incidence of flushing, GI discomfort, and potential for hepatotoxicity or gout.

23.8 Pharmacotherapy with Fibric Acid Drugs

  • Overview: Though now less used than statins, used for severely elevated triglycerides.

    • Key Drugs: gemfibrozil (Lopid) is commonly used, activating lipoprotein lipase to enhance lipid breakdown.

  • Adverse Effects: Mostly GI symptoms; risks include potential liver function disturbances and gallstone formation.

23.9 Pharmacotherapy with Miscellaneous Drugs for Dyslipidemias

  • Ezetimibe: Blocks cholesterol absorption in the intestine, often used with statins.

  • Omega-3 Fatty Acid Esters: Helps manage hypertriglyceridemia, derived from fish oils; minor side effects present.

  • Homozygous Familial Hypercholesterolemia Treatments:

    • Lomitapide: Inhibits MTP, indicated for genetic dyslipidemia.

    • Mipomersen: Inhibitor of apo B synthesis, used similarly to lomitapide with unique management protocols.

    • Both drugs have serious adverse effects, including hepatotoxic risks.

  • PCSK9 Inhibitors: Monoclonal antibodies (alirocumab, evolocumab) that enhance LDL clearance through receptor modulation; used for patients unresponsive to statins.

Nursing Practice Application

Assessment Prior to Administration

  • Complete health and drug history, monitor labs including liver function and lipid profiles.

Intervention Techniques

  • Educate patients regarding drug therapy, lifestyle changes, and monitoring for adverse reactions.

  • Dose explanations and adherence to therapeutic guidelines are crucial.

  • Directive for immediate reporting of severe adverse symptoms including musculoskeletal pain, jaundice, or significant GI distress.

Education and Self-Management

  • Promote adherence to prescribed treatment, dietary modifications, and regular follow-ups for therapeutic effectiveness and adverse event monitoring.

These notes encapsulate the comprehensive understanding required to manage lipid disorders effectively, emphasizing the synergy between pharmacotherapy, patient education, and lifestyle modifications.